Fennec Pharmaceuticals Inc. Share Price Nasdaq
Equities
CA31447P1009
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.675 USD | 0.00% | 0.00% | 0.00% |
Sales 2024 * | 62.94M 5.26B | Sales 2025 * | 67.21M 5.61B | Capitalization | 184M 15.36B |
---|---|---|---|---|---|
Net income 2024 * | 14M 1.17B | Net income 2025 * | 16M 1.34B | EV / Sales 2024 * | 2.92 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.74 x |
P/E ratio 2024 * |
13.2
x | P/E ratio 2025 * |
11.4
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.15% |
Latest transcript on Fennec Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 07/09/07 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 07/09/07 |
Mark Gowland
AUD | Comptroller/Controller/Auditor | 52 | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 70 | 25/11/25 |
Khalid Islam
CHM | Chairman | 67 | 25/14/25 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 07/09/07 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 126B | |
+24.67% | 118B | |
+24.25% | 27.87B | |
-17.74% | 20.95B | |
-15.73% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |